-+ 0.00%
-+ 0.00%
-+ 0.00%
NKGen Biotech Korea Corrects 2023 Sales to KRW 9.95 Billion From KRW 10.77 Billion
Share
Listen to the news
NKGen Biotech Korea Corrects 2023 Sales to KRW 9.95 Billion From KRW 10.77 Billion
  • NKGen Biotech Korea corrected its 2025 annual report on November 18, 2026, cutting reported 2023 sales to KRW 9.95 billion.
  • The previous sales figure was KRW 10.77 billion; the revision corrected a reporting error.
  • Recombinant protein export sales were revised to KRW 2.48 billion from KRW 3.3 billion.
  • Historical sales previously classified as cell therapies were reassigned to NK Vue Kit for 2024 and 2023.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NKGen Biotech Korea Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261118000208), on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending